CoChat
Sign Up
Cited by 612Menopause: Health Impacts and TreatmentsHormonal and reproductive studiesEstrogen and related hormone effects

The DOI matches its Crossref record; 228 of the 230 references it cites were found in a registry or an index.

Hormone therapy for preventing cardiovascular disease in post-menopausal women

Open access
Boardman, Henry MP, Hartley, Louise, Eisinga, Anne, Main, Caroline, Roqué i Figuls, Marta, Bonfill Cosp, Xavier, Gabriel Sanchez, Rafael, Knight, Beatrice·2015·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd002229.pub4PMC PMC10183715
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Evidence from systematic reviews of observational studies suggests that hormone therapy may have beneficial effects in reducing the incidence of cardiovascular disease events in post-menopausal women, however the results of randomised controlled trials (RCTs) have had mixed results. This is an updated version of a Cochrane review published in 2013. OBJECTIVES: To assess the effects of hormone therapy for the prevention of cardiovascular disease in post-menopausal women, and whether there are differential effects between use in primary or secondary prevention. Secondary aims were to undertake exploratory analyses to (i) assess the impact of time since menopause that treatment was commenced (≥ 10 years versus < 10 years), and where these data were not available, use age of trial participants at baseline as a proxy (≥ 60 years of age versus < 60 years of age); and (ii) assess the effects of length of time on treatment. SEARCH METHODS: We searched the following databases on 25 February 2014: Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE and LILACS. We also searched research and trials registers, and conducted reference checking of relevant studies and related systematic reviews to identify additional studies. SELECTION CRITERIA: RCTs of women comparing orally administered hormone therapy with placebo or a no treatment control, with a minimum of six months follow-up. DATA COLLECTION AND ANALYSIS: Two authors independently assessed study quality and extracted data. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for each outcome. We combined results using random effects meta-analyses, and undertook further analyses to assess the effects of treatment as primary or secondary prevention, and whether treatment was commenced more than or less than 10 years after menopause. MAIN RESULTS: We identified six new trials through this update. Therefore the review includes 19 trials with a total of 40,410 post-menopausal women. On the whole, study quality was good and generally at low risk of bias; the findings are dominated by the three largest trials. We found high quality evidence that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality, cardiovascular death, non-fatal myocardial infarction, angina, or revascularisation. However, there was an increased risk of stroke in those in the hormone therapy arm for combined primary and secondary prevention (RR 1.24, 95% CI 1.10 to 1.41). Venous thromboembolic events were increased (RR 1.92, 95% CI 1.36 to 2.69), as were pulmonary emboli (RR 1.81, 95% CI 1.32 to 2.48) on hormone therapy relative to placebo.The absolute risk increase for stroke was 6 per 1000 women (number needed to treat for an additional harmful outcome (NNTH) = 165; mean length of follow-up: 4.21 years (range: 2.0 to 7.1)); for venous thromboembolism 8 per 1000 women (NNTH = 118; mean length of follow-up: 5.95 years (range: 1.0 to 7.1)); and for pulmonary embolism 4 per 1000 (NNTH = 242; mean length of follow-up: 3.13 years (range: 1.0 to 7.1)).We performed subgroup analyses according to when treatment was started in relation to the menopause. Those who started hormone therapy less than 10 years after the menopause had lower mortality (RR 0.70, 95% CI 0.52 to 0.95, moderate quality evidence) and coronary heart disease (composite of death from cardiovascular causes and non-fatal myocardial infarction) (RR 0.52, 95% CI 0.29 to 0.96; moderate quality evidence), though they were still at increased risk of venous thromboembolism (RR 1.74, 95% CI 1.11 to 2.73, high quality evidence) compared to placebo or no treatment. There was no strong evidence of effect on risk of stroke in this group. In those who started treatment more than 10 years after the menopause there was high quality evidence that it had little effect on death or coronary heart disease between groups but there was an increased risk of stroke (RR 1.21, 95% CI 1.06 to 1.38, high quality evidence) and venous thromboembolism (RR 1.96, 95% CI 1.37 to 2.80, high quality evidence). AUTHORS' CONCLUSIONS: Our review findings provide strong evidence that treatment with hormone therapy in post-menopausal women overall, for either primary or secondary prevention of cardiovascular disease events has little if any benefit and causes an increase in the risk of stroke and venous thromboembolic events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd002229.pub4

Cites

228 of 228 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 21

  1. Hsia, 2006, Conjugated equine estrogens and coronary heart disease, Archives of Internal Medicine, 291, 1701
  2. Grady, 2002, Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II), JAMA, 288, 49, 10.1001/jama.288.1.49 · DOI
  3. Madsen, 2003, Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women, Journal of Thrombosis and Haemostasis, 1, 1984, 10.1046/j.1538-7836.2003.00362.x · DOI
  4. Pagliaro D Tangalakis K Kingwell B Craven R Carey M Stojanovska L The effects of hormone replacement therapy (HRT) on performance, cardiovascular parameters and bone resorption in post menopausal 'masters' athletes Proceedings of the 3rd Congress of the Australasian Menopause Society; 1999; Cairns 1999
  5. Post, 2003, Route of HRT administration and risk factors for venous thrombosis: A randomized, placebo-controlled study in healthy postmenopausal women, International Journal of Obstetrics and Gynecology, 83, 35
  6. Gallagher, 2012, Bazedoxifene/conjugated estrogens: Effects on bone mineral density and bone turnover markers in a double-blind, randomised, placebo- and active-controlled phase 3 study, Osteoporosis International, 23, S63
  7. Mirkin, 2012, Effects of bazedoxifene/conjugated estrogens on coagulation parameters in a 1-year, randomized, placebo-and active-controlled, phase 3 trial of postmenopausal women, Endocrine Reviews, 33, 3 Meeting Abstr
  8. Ylikorkala, 1999, Effects of a 1-year pulsed progestogen, constant estrogen hormone replacement therapy regimen, Prefest, on serum lipid levels in postmenopausal women, European Journal of Obstetrics, Gynecology, and Reproductive Biology, 86, S18
  9. Naftolin, 2012, Adverse events during four years of daily oral conjugated estrogen or transdermal estradiol plus cyclic oral progesterone treatment in recently menopausal women: The KRONOS early estrogen prevention study (KEEPS), Menopause, 19, 1402
  10. Howard, 2011, The early versus late intervention trial with estradiol (ELITE), Climacteric, 14, 35
  11. Curb, 2006, Venous thrombosis and conjugated equine estrogen in women without a uterus, Archives of Internal Medicine, 166, 772, 10.1001/archinte.166.7.772 · DOI
  12. Cushman, 2004, Estrogen plus progestin and risk of venous thrombosis, JAMA, 292, 1573, 10.1001/jama.292.13.1573 · DOI · Paper page
  13. Maat, 2007, Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after long term hormone replacement therapy, Thrombosis and Haemostasis, 97, 234, 10.1160/TH06-08-0426 · DOI
  14. Grady, 1998, Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics, Controlled Clinical Trials, 19, 314, 10.1016/S0197-2456(98)00010-5 · DOI · Paper page
  15. Hendrix, 2006, Effects of conjugated equine estrogen on stroke in the women's health initiative, Circulation, 113, 2425, 10.1161/CIRCULATIONAHA.105.594077 · DOI
  16. Hsia, 2006, Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative, Archives of Internal Medicine, 166, 357, 10.1001/archinte.166.3.357 · DOI
  17. Manson, 2003, Estrogen plus progestin and the risk of coronary heart disease, New England Journal of Medicine, 349, 523, 10.1056/NEJMoa030808 · DOI · Paper page
  18. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014
  19. Stefanick, 2003, The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants, Annals of Epidemiology, 13, S78, 10.1016/S1047-2797(03)00045-0 · DOI
  20. Tofteng, 2002, Two Polymorphisms in the Vitamin D Receptor Gene—Association With Bone Mass and 5-Year Change in BoneMass With or Without Hormone-Replacement Therapy inPostmenopausal Women: The Danish OsteoporosisPrevention Study, Journal of Bone and Mineral Research, 17, 1535, 10.1359/jbmr.2002.17.8.1535 · DOI
  21. Wassertheil-Smoller, 2003, Effect of estrogen plus progestin on stroke in postmenopausal women, JAMA, 289, 2673, 10.1001/jama.289.20.2673 · DOI

Cited by

Sorted by citations

See all 612

Related

See all

Metadata

Authors
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B.
Affiliations
  • John Radcliffe Hospital (GB)
  • University of Warwick (GB)
  • National Institute for Health and Care Research (GB)
  • Cancer Research UK Clinical Trials Unit (GB)
  • CIBER Epidemiología y Salud Pública (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 171 Edifici Casa de Convalescència Barcelona Catalunya Spain 08041
  • CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona; Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret, 167 Pavilion 18 (D-13) Barcelona Catalunya Spain 08025
  • Hospital Universitario de la Paz, Universidad Autónoma de Madrid; Instituto de Investigacion IdiPAZ, Red Espanola de Investigacion Cardiovascular RD/12/0042/0008; Diego De Leon 62 Planta 9 Madrid Spain 28006
  • University of Exeter (GB)
ORCID
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2015-03-10
Volume
2015
Issue
8
Pages
CD002229-CD002229
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd002229.pub4
PMC
PMC10183715
OpenAlex
W1927817986
Cited by
612
References
230
Citations by year
2026: 35 · 2025: 57 · 2024: 69 · 2023: 64 · 2022: 42 · 2021: 63 · 2020: 46 · 2019: 60 · 2018: 48 · 2017: 50 · 2016: 32 · 2015: 26
FWCI
7.83
Type
journal article
Language
en
Open access
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
hormone therapy, postmenopausal women, cardiovascular disease prevention, primary prevention, secondary prevention, stroke risk, venous thromboembolism, myocardial infarction, all-cause mortality, cardiovascular mortality, time since menopause, treatment duration, oral hormone therapy, menopause, cardiovascular risk factors, cardiovascular risk reduction
MeSH terms
Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Cause of Death, Female, Humans, Middle Aged, Primary Prevention, Estrogen Replacement Therapy, Postmenopause, Hormone Replacement Therapy, Stroke, Venous Thromboembolism, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review